• Most Popular
  • Most Shared

Eli Lilly wins ok for dog separation anxiety drug

Wed Apr 25, 2007 8:00am EDT

Stocks

   

BOSTON, April 25 (Reuters) - Drugmaker Eli Lilly and Co. (LLY.N) said on Wednesday that it won U.S. regulatory approval for its drug to treat separation anxiety in dogs.

The drug, Reconcile, is one of a class of drugs known as selective serotonin reuptake inhibitors, or SSRIs, which are also used to treat human depression.

((Reporting by Toni Clarke, editing by Gerald E. McCormick; Reuters Messaging, toni.clarke.reuters.com@reuters.net, 617-367-4165)) Keywords: LILLY/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN6989


More from Reuters

Joint Terminal Attack Controller SSgt Clinton J. Herbison, a U.S. Airman from the 817 Expeditionary Air Support Operations Squadron (EASOS) takes a break during a night mission near Honaker Miracle camp at the Pesh valley of Kunar Province August 12, 2009. Credit: REUTERS/Carlos Barria

Pictures of the Year

A look at the best photos of 2009.  Slideshow 

    PICTURES
    The Dalai Lama jokes with a nasal spray after being asked his opinion on the swine flu during a press conference after his first lecture in Lausanne, Switzerland, August 4, 2009. REUTERS/ Valentin Flauraud

    What a wacky year it's been...

    Um, what's up the Dalai Lama's nose? "Oddly Enough" editor Bob Basler rounds up the goofiest photos of the year.  Full Article 

    Oddly Enough
    A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
    Political Risk in 2010:

    Don't say we didn't warn you

    With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

    Global Markets